ALX ONCOLOGY HOLDINGS INC
ALX Oncology is a clinical-stage biotechnology company focused on developing novel therapies to treat cancer and extend patient survival. The company operates as a biopharmaceutical enterprise advancing a pipeline of immunotherapy and antibody-drug conjugate candidates designed to address significant unmet needs in… From the company’s description.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What ALX ONCOLOGY HOLDINGS INC does
In the company’s own words
ALX Oncology is a clinical-stage biotechnology company focused on developing novel therapies to treat cancer and extend patient survival. The company operates as a biopharmaceutical enterprise advancing a pipeline of immunotherapy and antibody-drug conjugate candidates designed to address significant unmet needs in oncology.
The company's lead product candidate is evorpacept, a CD47 blocking fusion protein in clinical development as a combination therapy with other anti-cancer agents. Evorpacept is engineered with a high-affinity CD47 binding domain derived from SIRPα fused to an inactivated Fc domain, designed to overcome limitations of competing CD47 blockers that incorporate active Fc regions. The inactive Fc approach is intended to minimize hematologic toxicities while maintaining antibody-like pharmacokinetics and enabling combination with multiple anti-cancer agents. Evorpacept is being evaluated across multiple oncology indications including HER2-positive breast cancer, gastric and gastroesophageal junction cancer, multiple myeloma, and non-Hodgkin lymphoma through company-sponsored trials and investigator-sponsored collaborations.
The company's second pipeline candidate is ALX2004, a novel epidermal growth factor receptor-targeted antibody-drug conjugate featuring a proprietary topoisomerase I inhibitor payload and enhanced linker stability. ALX2004 was designed in-house and entered Phase 1 clinical trials in August 2025 for patients with EGFR-expressing solid tumors.
ALX Oncology has established strategic collaborations with major pharmaceutical companies including Jazz Pharmaceuticals, Sanofi, and academic institutions like MD Anderson Cancer Center to advance its development programs. The company has treated approximately 800 subjects with evorpacept across multiple clinical trials to date. The company was founded to address fundamental challenges in CD47 blockade and to realize the full therapeutic potential of this target in immuno-oncology. ALX Oncology operates as a smaller reporting company and is classified as an emerging growth company. The company's website is www.alxoncology.com.
Company details
- Sector
- Healthcare
- Industry
- Pharmaceutical Preparations
- Headquarters
- SOUTH SAN FRANCISCO, CA
- Fiscal year end
- December
- CIK
- 1810182
- SIC
- 2834
Financial performance, year by year
Fiscal 2020–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns ALX ONCOLOGY HOLDINGS INC — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Largest fund holders · ALX ONCOLOGY HOLDINGS INC’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Could not be determined for this company: bond issues.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do ALX ONCOLOGY HOLDINGS INC and its peers compare on margins and cash generation over ten years?”
- “Where did five years of ALX ONCOLOGY HOLDINGS INC's earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in ALX ONCOLOGY HOLDINGS INC's last four quarterly filings that the numbers alone won't show?”